# A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants

> **NCT06977880** · PHASE1 · COMPLETED · sponsor: **Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)** · enrollment: 80 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY4292009
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06977880
- **Lead sponsor:** Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-19
- **Primary completion:** 2026-03-20
- **Final completion:** 2026-03-20
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06977880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06977880, "A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06977880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*